Showing results (161-170 of 212) with videos related to
Sort By:
Pageof 22
Molecular Cancer Therapeutics|August 24, 2016
Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547Oona Delpuech, Claire Rooney, Lorraine Mooney, et al.Journal of Neurosurgery|May 30, 2020
The microenvironment in sporadic and neurofibromatosis type II-related vestibular schwannoma: the same tumor or different? A comparative imaging and neuropathology studyDaniel Lewis, Carmine A Donofrio, Claire O'Leary, et al.Cell Reports|April 18, 2019
Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung CancerHyejin Choi, Jiehui Deng, Shuai Li, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2013
Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytomaHemant K Bid, Aaron Kibler, Doris A Phelps, et al.Journal of Hepatology|November 14, 2009
AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC)Hung Huynh, Van Chanh Ngo, Heng Nung Koong, et al.JMIR Formative Research|February 18, 2025
Snowball Group Usability Testing for Rapid and Iterative Multisite Tool Development: Method Development StudyKatherine L Dauber-Decker, David Feldstein, Rachel Hess, et al.Journal of Neurology, Neurosurgery, and Psychiatry|June 18, 2018
Schwannomatosis: a genetic and epidemiological studyD Gareth Evans, Naomi L Bowers, Simon Tobi, et al.Journal of Medical Genetics|August 29, 2024
Genetic findings in people with schwannomas who do not meet clinical diagnostic criteria for NF2-related schwannomatosisMiriam J Smith, Cristina Perez-Becerril, Mwee van der Meer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2012
Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasisOsamu Takahashi, Ritsuko Komaki, Paul D Smith, et al.Oncotarget|October 21, 2017
Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activityNicola J Curtis, Lorraine Mooney, Lorna Hopcroft, et al.Pageof 22